With the recent Southwest Oncology Group (SWOG) publication of their metastatic prostate cancer clinical trial results, which concluded that orchiectomy and utamide as maximal androgen blockade (MAB) therapy vs orchiectomy alone does not signi®cantly improve survival (NCI 0105), and the 1989 publication from the same cooperative group indicating a 24% improvement in survival for MAB therapy with leuprolide and¯utamide versus leuprolide alone (NCI 0036), clinicians may well be undecided about the likelihood of clinical bene®ts with¯utamide in combination with medical or surgical castration. To better characterize this important therapeutic decision, we assessed the survival bene®t of MAB therapy with¯utamide through a meta-analysis of up-to-date information from studies reportedaconducted from 1989 through 1998.
Introduction
Prostate cancer is the most common malignancy among American men, and the second most common cause of cancer deaths. As men with prostate cancer live longer, an increasing number are developing metastatic disease, requiring treatments with various hormonal therapies, each with different, and often severe toxicity. Endocrine therapy is the primary treatment for metastatic prostate cancer, primarily medical or surgical castration. Labrie et al 1 proposed that better results might be obtained with maximal androgen blockade (MAB) therapy utilizing anti-androgen administration in conjunction with medical or surgical castration by blocking androgen production outside of the testes; however, uncertainty has existed about the magnitude of bene®t with MAB.
Recently, meta-analyses, based on information from 5710 patients and 22 randomized trials, indicated that the bene®ts of MAB with anti-androgens such as¯uta-mide were not statistically different from the placebo results. 2 Large clinical trials have found varying results with¯utamide therapy. The recently analyzed Southwest Oncology Group (SWOG) sponsored trial (NCI 0105) of orchiectomy plus¯utamide versus orchiectomy alone found a 10% survival bene®t with¯utamide; however, as this study had been sized to detect a larger difference, the result was not statistically signi®cant. The previously reported SWOG study of¯utamide plus leuprolide versus leuprolide alone has found a 24% survival bene®t. 3, 4 The primary goal of this report is to assess the survival bene®t in advanced prostate cancer of MAB using¯utamide versus castration alone through a conventional meta-analysis of peer-reviewed published randomized controlled trials.
Methods
The study used techniques for meta-analysis of randomized clinical trials as previously described. 5 Brie¯y, a study protocol was designed prospectively to de®ne the study objectives, eligibility criteria for inclusion of trials, key data elements to be extracted, and analytic methods to be used. Computerized data entries were checked against forms and articles for accuracy. All published phase III randomized clinical trials that included¯uta-mide and medical or surgical castration for stage D patients and were identi®ed by the PCTCG in their earlier publication were included in this study. 4,6 ± 14 Additional peer-reviewed published studies that were completed since the PCTCG effort were also abstracted. 3, 15 Data that were available only in abstract form or in non-peer reviewed literature were excluded. 9, 14 Letters were sent to the principle authors of each study requesting updated information. Data from each eligible new and updated study were extracted using forms developed previously. 5 Extracted data included hazard ratios with accompanying standard errors; P-values; numbers of deaths in each treatment arm; annual survival probabilities as measured from graphically displayed survival curve; and the number of patients at risk at the beginning of each year.
Statistical analyses
The primary objective of this study was to form a combined estimate and con®dence interval for the hazard ratio (RR) summarizing the effect of¯utamide treatment on overall survival. Only two studies provided direct estimates for the hazard ratio. Where this was not available, one of two methods was used to develop the RR estimate based on the best available information from the article. 5 In the ®rst method, P-values were combined with data on the total number of deaths to construct an estimate of the logrank statistic and the log hazard ratio. 16 The second method used the measured annual survival probabilities and numbers of individuals who died or who remained at risk to construct annual life tables. 17 The life tables were used to estimate a log hazard ratio based on a discrete proportional hazards model. Estimates of log hazard ratios for each study and their standard errors were then combined using a random effects meta-analysis based on the method of DerSimonian and Laird. 18 The directly extracted estimate of the log hazard ratio was used if available. If not, the`P-value' approximation was used. Finally, the discrete proportional hazards approximation was used if neither of the other two methods were possible.
Results
We retrieved information on 4128 patients based on nine RCTs. Characteristics of the studies are summarized in Table 1 While all studies included in the previously published meta-analysis were included in this study, studies by Eisenberger et al 3 and Zalcberg et al 15 were added for this analysis. Six studies used goserelin, one study used leuprolide, and four studies included orchiectomy patients. Flutamide 250 mg three times a day or placebo was used in all studies. Only 98 patients had stage C tumors. The mean ages of all the patients was between 70 and 75 y in all studies.
All nine studies provided suf®cient information to estimate the log hazard ratio and its standard error ( Table 2 ). The`P-value method' was the primary method of extraction. The log hazard ratios tended to be negative, suggesting a bene®cial effect for MAB therapy. The pooled estimate reveals a 10% improvement in overall survival with¯utamide (RR 0.90, 95% con®-dence intervals (CI) 0.79, 1.00), (Figure 1 ). Table 3 compares this literature-based meta-analysis with the prior PCTCG patient-level meta-analysis. Of note, while the relative risks are similar, the 95% con®dence intervals are narrower in the current study. 
Discussions
This meta-analysis focused on published randomized controlled rials with¯utamide as the non-steroidal antiandrogen agent in maximal androgen blockade. We found a statistically signi®cant 10% prolongation of overall survival in patients with advanced prostate cancer who received maximal androgen blockage therapy with utamide. Our results represent the ®rst published metaanalytic effort that includes information from studies published as recently as 1998, with the most recent study including 1385 patients, over twice as many patients as in the largest previously published trial. 3, 4 While this recent study found that¯utamide was not associated with`statistically signi®cant' improvements in survival, the overall estimate of bene®t of the trial (RR 0.88, 95% CI 0.70, 1.10) is remarkably similar to our meta-analysis estimate (RR 0.90, CI 0.79, 1.00). 3 Taken together, the results of all of the individual clinical trials and this meta-analysis suggest that the likely magnitude of the bene®t of¯utamide therapy is unlikely to be in the range of 25%, as reported in the original NCI 0036 trial, 3 and more likely to be in the range of a 10% bene®t, as reported in the NCI 0105 trial. 4 Many clinicians are awaiting reports from meta-analyses by the PCTCG, the Agency for Health Care Policy and Research evidence-based literature review of hormonal therapies (conducted by the Blue Cross and Blue Shield Technology Assessment Center), and the American Society of Clinical Oncology Metastatic Prostate Cancer Guidelines Panel in order to fully evaluate the effect of MAB therapy with¯utamide. The patient-level PCTCG effort includes one additional study of 148 patients that was conducted by the marketing department of a pharmaceutical company and one study of 122 patients that includes patients in which the LhRH agonist control arm also received cyproterone acetate (representing only 6% of the total patient numbers included in this analysis). It is unlikely that the additional information from these patients would have resulted in much change to our estimates.
Our study has important methodologic implications. Over the last decade, there has been a growing interest in the use of systematic evidence based reviews with metaanalysis. The general validity of meta-analyses of aggregated literature has been questioned. 20, 21 Meta-analyses of the literature on small trials do not reliably predict the results of`mega-trials' or, when more than one metaanalysis has been conducted, reliably agree with each other. Additionally, conclusions from meta-analyses of the literature do not always agree with those obtained from individual patient-level meta-analyses. 22 ± 26 Many of the discrepancies relate to the speci®c selection of studies used for comparison and to the selection of outcomes in the analyses. 24 When investigators carefully search for the reasons underlying the discrepancies, an explanation is usually identi®ed. 24 While individual patient-level metaanalyses and large phase III clinical trials are believed to provide more valid answers than literature-based metaanalyses, 20, 25 large trials and individual patient-level meta-analyses are not always available. 26 Literaturebased meta-analyses represent the only feasible alternative in this situation.
Operational differences between patient-level and literature-based meta-analyses are also important to consider. While patient-level based efforts are felt to be the gold standard for evaluating data from several phase III trials, these studies are expensive to carry out, dif®cult to update at frequent intervals, and require Constructed annual life tables were used to estimate a log hazard ratio based on a discrete proportional hazards model. c Directly extracted estimate of the log hazard ratio was used. Figure 1 Relative risk for¯utamide plus medical or surgical castration vs medical or surgical castration alone from nine individual phase III randomized trials and summary statistics for the meta-analysis of these studies. Table 3 Hazard ratios and 95% con®dence intervals using alternative methods for estimating hazard ratios for survival data (this study) and comparison with results from the 1995 PCTCG analysis Table 1   b The NCI 0105 study is included in this analysis, but was not included in the earlier PCTCG study. ) has been published only in non peerreviewed form and a second study (Ferrari 19 ) is excluded because patients in the LhRH control arm also received cyproterone acetate.
extensive collaboration from multiple investigators. In contrast, the methods used in this study were ef®cient and the project was able to be completed in less than one year. We worked directly with the Cochrane Collaboration on Prostate Cancer in this effort, 25 and were able to obtain information on 4128 patients reported in nine studies, whereas in the earlier literature-based meta-analysis, information was available on only 2666 patients who participated in seven studies of¯utamide vs placebo. 27 Almost all of the principal investigators were approached for participation at the First Meeting of the Cochrane Collaboration on Prostate Cancer and the Working Group Effort of the Prostate Cancer Trialists Group in Oxford in June 1997, thereby minimizing the costs and time associated with recruitment to this effort. Because all of the collaborators had recently submitted updated survival curves to the PCTCG effort, it was relatively easy to submit updated studylevel information for this study. As part of a recently funded American Cancer Society project, the information included in this meta-analysis and in the Blue CrossaBlue Shield Evidence Based Review will be incorporated into a CD-ROM format as part of a prostate cancer evidence based review that will be included in the publications of the Cochrane Collaboration. This format will allow for timely updates of overviews on utamide therapy. The limitations of our study must be addressed. Because the analysis is based on individual studylevel results rather than patient-level results, we are not able to analyze information on LhRH agonists separately from the information with orchiectomy patients. The most recent NCI 0105 study provides evidence that¯utamide in conjunction with an orchiectomy is associated with limited clinical bene®t (10% RR), 3 while the earlier NCI 0036 suggests that¯utamide and an LhRH agonist was associated with a 24% improvement in overall survival rates. 4 The updated PCCTG effort should provide needed insight into the distinction between employing orchiectomy or an LhRH agonist in conjunction with¯utamide. Secondly, analyses based on subsets of patients with minimal and severe metastatic disease are important, but could not be evaluated in this literature based meta-analysis. Many prior clinical trials have shown differing bene®ts of¯utamide therapy that are dependent on the extent of prostate cancer at the time of study entry. Thirdly, no adjustments were made for age or comorbid medical illnesses in this analysis. Finally, this analysis addressed only¯utamide therapy. There has been an ongoing debate about which anti-androgen agents should be evaluated in overview analyses. We have focused on only one anti-androgen for several reasons. The two largest studies of maximal androgen blockade, are based on phase III clinical trial results from the Southwest Oncology Group. 3, 4 Also, the greater the heterogeneity of patient population, intervention, andaor outcome in overview analyses, the greater the likelihood that bene®t will be attributed to interventions that, in more homogenous studies, would be considered to be of marginal bene®t. 27 Additional meta-analysis efforts will include bicalutamide and nilutamide, which have different toxicity pro®les and anti-androgen binding activity.
Conclusions
Our meta-analysis suggests that MAB therapy with¯u-tamide is associated with a 10% improvement in overall survival when used in conjunction with an LhRH agonist or orchiectomy. Cost-effectiveness estimates suggest that utamide use would be in the range of $47 500 to $60 900 per year of life saved, a range that is associated with agents that are moderately cost-effective in clinical practice. 28 Physicians and patients should discuss the relative likelihood of bene®t and the out-of-pocket cost considerations and side effects of¯utamide therapy prior to making a decision to use this agent.
